Certara, Inc. (CERT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 244 | 286 | 336 | 354 | 385 | 419 | 408 | 380 |
| Operating profit | $m | 21 | 8 | ||||||
| Net profit | $m | -49 | -13 | 15 | -55 | -12 | -2 | -68 | 54 |
| EPS reported | $ | -0.01 | -0.44 | ||||||
| Operating cashflow per share | $ | 0.60 | 0.54 | ||||||
| Capex per share | $ | 0.17 | 0.14 | ||||||
| FCF per share | $ | 0.43 | 0.40 | ||||||
| Free cash flow | $m | 70 | 62 | ||||||
| Net debt | $m | -178 | 101 | ||||||
| Book value equity | $m | 1,063 | 967 | ||||||
| Book value per share | $ | 6.63 | 6.26 | ||||||
| Number of shares | m | 160.39 | 154.36 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.33 | 1.46 | ||||||
| P/S LTM | x | 3.37 | 3.46 | ||||||
| P/FCF LTM | x | 20.25 | 22.92 | ||||||
| EV/EBITDA LTM | x | 14.72 | 14.83 | ||||||
| EV/Sales LTM | x | 2.95 | 3.29 | ||||||
| Earnings Yield LTM | % | -0.11% | -5.58% | ||||||
| FCF Yield | % | +4.94% | +4.36% | ||||||
| Quality | |||||||||
| ROE | % | -0.15% | -6.66% | ||||||
| ROIC | % | -0.31% | +0.59% | ||||||
| Operating margin | % | +5.02% | +1.86% | ||||||
| Gross margin | % | +61.53% | +58.33% | ||||||
| FCF/Sales | % | +16.66% | +15.09% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +8.75% | +6.05% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | +17.41% | +3.73% | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 6.12 | 0.21 | ||||||
| Net Debt/EBITDA | x | -2.12 | 1.29 | ||||||
| EBIT/Net interest | x | 1.06 | 0.19 | ||||||
| Net debt/market cap | % | +0.81% | +23.63% | ||||||
| Net debt/Equity | x | -0.17 | 0.10 | ||||||
| Gross debt/equity | x | 0.01 | 0.30 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free